Cortical Synaptogenesis and Behavioural Consequences in CNS Lesioned Animals Receiving Neurotrophic Factor Therapy

  • A. Claudio Cuello
Part of the Advances in Alzheimer Disease Therapy book series (AADT)


The ultimate goal in neurodegenerative disease therapy is the preservation of neuronal somata and their synaptic connections. In this regard, there is overwhelming experimental evidence that these objectives can be met with the application of neurotrophic factors in diverse lesion models leading to anterograde or retrograde neuronal degeneration. The issue of whether neurotrophic factor administration can re-establish or regenerate new synaptic contacts has been recently reviewed in the context of future neurotrophic factor based therapies (Cuello and Thoenen, 1995). However, much has yet to be learned on the limits and possible undesirable effects of this approach. Thus, in recent attempts to apply purified mouse nerve growth factor (NGF) in Alzheimer’s disease (AD) the treatment had to be interrupted due to weight loss and cefalalgias (Sieger et al., 1993). Indeed, excessive NGF offering provokes ectopic synaptic formation of peptide-containing terminals within the white matter of transgenic mice overexpressing chick NGF, produced by oligodendrocytes during early post-natal stages (Ma et al., 1995). Will trophic therapy, therefore, be undesirable in AD? I would like to propose that neurotrophic factors (NTFs) have a defined opportunity in AD therapy provided that some basic conditions are met. These should be, firstly, early treatment, at a stage when there is sufficient regenerative capacity left in the diseased brain to respond to NTFs, an approach which is currently hampered by the lack of presymptomatic biological diagnosis. Secondly, much has yet to be learned about the specificity, interactions and dosage of NTFs capable of provoking synaptogenesis in the cerebral cortex accompanied by desirable behavioural effects. Thirdly, the field anxiously awaits a suitable animal model for AD where these (and other) propositions can be properly and exhaustively investigated.


Nerve Growth Factor Nerve Growth Factor Treatment Cholinergic Marker Human Nerve Growth Factor Human Recombinant Nerve Growth Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Berardi N, Cellerino A, Domenici L, Fagiolini M, Pizzorusso T, Cattaneo A and Maffei L (1994): Monoclonal antibodies to nerve growth factor affect the postnatal development of the visual system. Proc Natl Acad Sci USA 91:684–688.PubMedCrossRefGoogle Scholar
  2. Buell SJ and Coleman P (1981): Quantitative evidence for selective dendritic growth in normal human aging but not in senile dementia. Brain Res 21:423–41.Google Scholar
  3. Burgos I, Cuello AC, Liberini P, Pioro EP and Masliah E (1995): NGF-mediated synaptic sprouting in the cerebral cortex of lesioned primate brain. Brain Res 692:154–160.PubMedCrossRefGoogle Scholar
  4. Cabelli RJ, Hohn A and Shatz CJ (1995): Inhibition of ocular dominance column formation by infusion oT-4/5 or BDNF. Science 267:1662–1666.PubMedCrossRefGoogle Scholar
  5. Chen KS, Masliah E, Mallory M and Gage FH (1995): Synaptic loss in cognitively impaired aged rats is ameliorated by chronic human nerve growth factor infusion. Neuroscience 68:19–27.PubMedCrossRefGoogle Scholar
  6. Cuello AC (1994): Trophic factor therapy in the adult CNS: remodelling of injured basalo-cortical neurons. Progr Brain Res 100:213–221.CrossRefGoogle Scholar
  7. Cuello AC, Garofalo L, Kenigsberg RL and May singer D (1989): Gangliosides potentiate in vivo and in vitro effects of nerve growth factor on central cholinergic neurons. Proc Natl Acad Sci USA 86:2056–2060.PubMedCrossRefGoogle Scholar
  8. Cuello AC and Thoenen H (1995): The pharmacology of neurotrophic factors. In: Pharmacological sciences: perspectives for research and training in the late 1990s, Cuello AC and Collier B, eds. Basel: Birkhauser, pp. 241–245.Google Scholar
  9. Dosky ST and Scheff SW (1990): Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 27:457–464.CrossRefGoogle Scholar
  10. Ferrari G, Anderson BL, Stephens RM, Kaplan DR and Greene LA (1995): Prevention of apoptotic neuronal death by GM1 ganglioside. Involvement of Trk neurotrophin receptors. J Biol Chem 270:3074–3080.PubMedCrossRefGoogle Scholar
  11. Figueiredo BC, Pluss K, Skup M, Otten U and Cuello AC (1995): Acidic FGF induces and its NA in the injured neocortex of adult animals. Mol Brain Res 33:1–6.PubMedCrossRefGoogle Scholar
  12. Fischer W, Bjorklund A, Chen K and Gage FH (1991): NGF improves spatial memory in aged rodents as a function of age. J Neurosci 11:1889–1906.PubMedGoogle Scholar
  13. Fischer W, Wictorin K, Bjorklund A, Williams L, Varon S and Gage FH (1987): Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329: 65–68.PubMedCrossRefGoogle Scholar
  14. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagoplan S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, Monlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J (1995): Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 37:3523–527.Google Scholar
  15. Garofalo L and Cuello AC (1994): Nerve growth factor and the monosialoganglioside GM1: Analogous and different in vivo effects on biochemical, morphological, and behavioral parameters of adult cortically lesioned rats. Exp Neurol 125:195–217.PubMedCrossRefGoogle Scholar
  16. Garofalo L and Cuello AC (1995): Pharmacological characterization of nerve growth factor and/or monosialoganglioside GM1 effects on cholinergic markers in the adult lesioned brain. J Pharmacol Exp Ther 272:527–545.PubMedGoogle Scholar
  17. Garofalo L, Ribeiro-da-Silva A and Cuello AC (1992): Nerve growth factor-induced synaptogenesis and hypertrophy of cortical cholinergic terminals. Proc Natl Acad ScSA 89:2639–2643.CrossRefGoogle Scholar
  18. Garofalo L, Ribeiro-da-Silva A and Cuello AC (1993): Potentiation of nerve growth factor-induced alterations in cholinergic fibre length and presynaptic terminal size in cortex of lesioned rats by the monosialoganglioside GM1. Neuroscience 57:21–40.PubMedCrossRefGoogle Scholar
  19. Holtzman DM, Li Y, Parada LF, Kinsman S, Chen C-K, Valletta JS, Zhou J, Long JB and Mobley WC (1992): pl40trk NA marks NGF-responsive forebrain neurons: Evidence that trk gene expression is induced by NGF. Neuron 9:465–478.Google Scholar
  20. Kawaja MD, Rosenberg MB, Yoshida K and Gage FH (1992): Somatic gene transfer of nerve growth factor promotes the survival of axotomized septal neurons and the regeneration of their axons in adult rats. J Neurosci 12:2849–2864.PubMedGoogle Scholar
  21. Knipper M, Leung LS, Zhao D and Rylett RJ (1994): Short-term modulation of glutamatergic synapses in adult rat hippocampus by NGF. Neuroreport 5:2433–2436.PubMedCrossRefGoogle Scholar
  22. Kolb B, Côté S, Ribeiro-da-Silva A and Cuello AC (1996a): NGF treatment prevents dendritic atrophy and promotes recovery of function after cortical injury. Neuroscience submitted.Google Scholar
  23. Kolb B, Gorny G, Côté S, Ribeiro-da-Silva A and Cuello AC (1996b): Nerve growth factor stimulates growth of cortical pyramidal neurons in young adult rats. Brain Res Submitted.Google Scholar
  24. Lapchak PA and Hefti F (1991): Effect of recombinant human nerve growth factor on presynaptic cholinergic function in rat hippocampal slices following partial septohippocampal lesions: Measures of [3H]acetylcholine synthesis, [3H]acetylcholine release and choline acetyltransferase activity. Neuroscience 42:639–649.PubMedCrossRefGoogle Scholar
  25. Lewin GR and Barde Y-A (1996): Physiology of the Neurotrophins. In: Annual Review of Neuroscience, Cowan WM, Shooter EM, Stevens CF and Thompson RF, eds. Palo Alto, CA: Annual Reviews Inc., pp. 289–317.Google Scholar
  26. Liberini P, Pioro EP, Maysinger D and Cuello AC (1994): Neocortical infarction in subhuman primates leads to restricted morphological damage of the cholinergic neurons in the nucleus basalis of Meynert. Brain Res 648:1–8.PubMedCrossRefGoogle Scholar
  27. Ma W, Ribeiro-da-Silva A, Noel G, Julien J-P and Cuello AC (1995): Ectopic substance P and calcitonin gene-related peptide immunoreactive fibers in the spinal cord of transgenic mice over-expressing nerve growth factor. Eur J Neurosci 7:2021–2035.PubMedCrossRefGoogle Scholar
  28. Masliah E, Terry RD, Alford M, Deresa R and Hansen LA (1991): Cortical and subcortical patterns of synaptophysin-like immunoreactivity in Alzheimer’s disease. Am J Pathol 138:235–246.PubMedGoogle Scholar
  29. Maysinger D, Herrera-Marschitz M, Goiny M, Ungerstedt U and Cuello AC (1992): Effects of nerve growth factor on cortical and striatal acetylcholine and dopamine release in rats with cortical devascularizing lesions. Brain Res 577:300–305.PubMedCrossRefGoogle Scholar
  30. Mervis RF, Pope D, Lewis R, Dvorak RM and Williams LR (1991): Exogenous nerve growth factor reverses age-related structural changes in neocortical neurons in the aging rat. A quantitative Golgi study. Ann NY Acad Sci 640:95–101.PubMedGoogle Scholar
  31. Pioro EP and Cuello AC(1990): Distribution of nerve growth factor receptor-like immunoreactivity in the adult rat central nervous system: Effect of colchicine and correlation with the cholinergic system-I. Forebrain. Neuroscience 24:57–87.CrossRefGoogle Scholar
  32. Scali C, Casamenti F, Pazzagli M, Bartolini L and Pepeu G (1994): Nerve growth factor increases extracellular acetylcholine levels in the parietal cortex and hippocampus of aged rats and restores object recognition. Neurosci Lett 170:117–120.PubMedCrossRefGoogle Scholar
  33. Schuman EM and Madison DV (1994): Locally distributed synaptic potentiation in the hippocampus. Science 263:532–536.PubMedCrossRefGoogle Scholar
  34. Seiger A, Nordberg A, Von Hoist H, Backman L, Ebendal T, Alafuzoff I, Amberla K, Hartvig P, Herlitz A, Lilja A, Lundqvist H, Langstrom B, Meyerson B, Persson A, Viitanen M, Winblad B and Olson L (1993): Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy. Behav Brain Res 57 255–261.PubMedCrossRefGoogle Scholar
  35. Terry RD, Masliah E, Salmon DP, Butters N, Deresa R, Hill R, Hansen LA and Katzman R (1991): Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580.PubMedCrossRefGoogle Scholar
  36. Williams LR, Rylett RJ, Ingram DK, Joseph JA, Moises HC, Tang AH and Mervis RF (1993): NGF affects the cholinergic biochemistry and behaviour of aged rats. Prog Brain Res 98:241–250.CrossRefGoogle Scholar
  37. Yoshida K and Gage FH (1992): Cooperative regulation of nerve growth factor synthesis and secretion in fibroblasts and astrocytes by fibroblast growth factor and other cytokines. Brain Res 569:14–25.PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 1997

Authors and Affiliations

  • A. Claudio Cuello
    • 1
  1. 1.Dept. of Pharmacology & TherapeuticsMcGill UniversityMontrealCanada

Personalised recommendations